Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells Yabing Chen1,2 #, Chun Pan1,2#, Xiaotong Wang3, Dihui Xu1,2, Yuhan Ma1,2 , Jianhang Hu1,2 , Peilin Chen1,2, Zou Xiang4, Qiu Rao3, Xiaodong Han1,2 1 Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing 210093, China 2 Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing 210093, China 3 Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China 4 Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong China #These authors contributed equally to this study. Corresponding authors: Qiu Rao,
[email protected], Department of Pathology, Jinling Hospital, Nanjing 210002, China; Xiaodong Han,
[email protected], Immunology and Reproduction Biology Laboratory, Medical School, Nanjing University, Nanjing 210093, China, Tel/fax: +86 25 83686497. 1 Table S1. Primary antibodies used in this study. Source Primary antibodies Catalog no. Working dilution Abcam Rabbit anti-METTL3 ab195352 WB, 1:2000 IHC, 1: 800 Abcam Mouse anti-FTO ab92981 WB, 1:1000 IHC, 1:400 Abcam Rabbit anti-ZEB1 ab203829 WB, 1:500 IHC Santa Cruz Biotechnology Mouse anti-ARHGDIB sc-376473 WB,1:500 Santa Cruz Biotechnology Mouse anti-E-cadherin sc-8426 WB,1:500 Santa Cruz Biotechnology Mouse anti-HNRNPD sc-166577 WB,1:500 Santa Cruz Biotechnology